TWST.NASDAQTwist Bioscience CORP
Form 4: Twist Bioscience CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Emily M. Leproust, Chief Executive Officer and a Director of Twist Bioscience Corp, sold 356,546 shares of common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 133,269 Common Stock at $26.66 ($3,552,952) on September 17, 2026; holds 901,696 after (Direct).
- Option exercise/conversion: acquired 75,439 Common Stock at $8.82 ($665,372) on September 17, 2026; holds 977,135 after (Direct).
- Open-market sale: disposed of 2,440 Common Stock at $151.46 ($369,566) on September 17, 2026; holds 974,695 after (Direct).
- Open-market sale: disposed of 6,644 Common Stock at $152.21 ($1,011,291) on September 17, 2026; holds 968,051 after (Direct).
- Open-market sale: disposed of 3,399 Common Stock at $153.40 ($521,417) on September 17, 2026; holds 964,652 after (Direct).
- Open-market sale: disposed of 4,175 Common Stock at $154.17 ($643,661) on September 17, 2026; holds 960,477 after (Direct).
- Open-market sale: disposed of 13,378 Common Stock at $155.46 ($2,079,701) on September 17, 2026; holds 947,099 after (Direct).
- Open-market sale: disposed of 9,097 Common Stock at $156.47 ($1,423,384) on September 17, 2026; holds 938,002 after (Direct).
- Open-market sale: disposed of 32,260 Common Stock at $157.49 ($5,080,498) on September 17, 2026; holds 905,742 after (Direct).
- Open-market sale: disposed of 232,173 Common Stock at $158.09 ($36,703,672) on September 17, 2026; holds 673,569 after (Direct).
- Open-market sale: disposed of 23,884 Common Stock at $159.53 ($3,810,250) on September 17, 2026; holds 649,685 after (Direct).
- Open-market sale: disposed of 14,493 Common Stock at $160.44 ($2,325,245) on September 17, 2026; holds 635,192 after (Direct).
- Open-market sale: disposed of 11,169 Common Stock at $161.49 ($1,803,715) on September 17, 2026; holds 624,023 after (Direct).
- Open-market sale: disposed of 2,565 Common Stock at $162.31 ($416,334) on September 17, 2026; holds 621,458 after (Direct).
- Open-market sale: disposed of 869 Common Stock at $163.39 ($141,988) on September 17, 2026; holds 620,589 after (Direct).
- Option exercise/conversion: disposed of 75,439 Employee Stock Option (right to buy) on September 17, 2026 (Direct).
- Option exercise/conversion: disposed of 133,269 Employee Stock Option (right to buy) on September 17, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $56,330,724 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Emily M. Leproust — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Stock | 133,269 | $27 | $3.6M | 901,696 |
| 2026-09-17 | Option exercise/conversion | Common Stock | 75,439 | $9 | $665.4K | 977,135 |
| 2026-09-17 | Open-market sale | Common Stock | 2,440 | $151 | $369.6K | 974,695 |
| 2026-09-17 | Open-market sale | Common Stock | 6,644 | $152 | $1.0M | 968,051 |
| 2026-09-17 | Open-market sale | Common Stock | 3,399 | $153 | $521.4K | 964,652 |
| 2026-09-17 | Open-market sale | Common Stock | 4,175 | $154 | $643.7K | 960,477 |
| 2026-09-17 | Open-market sale | Common Stock | 13,378 | $155 | $2.1M | 947,099 |
| 2026-09-17 | Open-market sale | Common Stock | 9,097 | $156 | $1.4M | 938,002 |
| 2026-09-17 | Open-market sale | Common Stock | 32,260 | $157 | $5.1M | 905,742 |
| 2026-09-17 | Open-market sale | Common Stock | 232,173 | $158 | $36.7M | 673,569 |
| 2026-09-17 | Open-market sale | Common Stock | 23,884 | $160 | $3.8M | 649,685 |
| 2026-09-17 | Open-market sale | Common Stock | 14,493 | $160 | $2.3M | 635,192 |
| 2026-09-17 | Open-market sale | Common Stock | 11,169 | $161 | $1.8M | 624,023 |
| 2026-09-17 | Open-market sale | Common Stock | 2,565 | $162 | $416.3K | 621,458 |
| 2026-09-17 | Open-market sale | Common Stock | 869 | $163 | $142.0K | 620,589 |
| 2026-09-17 | Option exercise/conversion | Employee Stock Option (right to buy) | 75,439 | — | — | 0 |
| 2026-09-17 | Option exercise/conversion | Employee Stock Option (right to buy) | 133,269 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (133,269 shares) |
| 2026-09-17 | Option exercise/conversion (75,439 shares) |
| 2026-09-17 | Open-market sale (2,440 shares) |
| 2026-09-17 | Open-market sale (6,644 shares) |
| 2026-09-17 | Open-market sale (3,399 shares) |
| 2026-09-17 | Open-market sale (4,175 shares) |
| 2026-09-17 | Open-market sale (13,378 shares) |
| 2026-09-17 | Open-market sale (9,097 shares) |
| 2026-09-17 | Open-market sale (32,260 shares) |
| 2026-09-17 | Open-market sale (232,173 shares) |
| 2026-09-17 | Open-market sale (23,884 shares) |
| 2026-09-17 | Open-market sale (14,493 shares) |
| 2026-09-17 | Open-market sale (11,169 shares) |
| 2026-09-17 | Open-market sale (2,565 shares) |
| 2026-09-17 | Open-market sale (869 shares) |
| 2026-09-17 | Option exercise/conversion (75,439 shares) |
| 2026-09-17 | Option exercise/conversion (133,269 shares) |
Keywords
insider transaction, Form 4, TWST, Twist Bioscience Corp, bearish, Emily M. Leproust
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.